摘要：背景：上消化道出血是肝硬化的过程中的发病率和死亡率的最常见的原因之一。肝病患者经常有止血异常，如纤溶亢进。因此，抗纤溶氨基酸作为补充的干预措施拟被用于主要治疗上消化道出血的肝病患者中。目的：为了评估抗纤溶氨基酸对上消化道出血伴有急性或慢性肝脏疾病患者的利害关系。检索方法：我们调查登记的Cochrane肝胆组对照试验（2012年6月11日），登记在Cochrane图书馆（2012年第5期的12）的Cochrane中心对照试验，美国医学索引（奥维SP）（1946年至2012年6月），荷兰医学文摘（1974年到2012年）（奥维SP），科学引文索引扩展（1900年至2012年6月），LILACS（1982年到2012年），世界卫生组织的临床试验（2012年6月18日），和Metaregister对照试验（2012年6月18号）。我们核对检索刊物的参考文献目录。选择标准：不论致盲，语言或出版物形式的随机临床试验进行评估利害关系。用于观察研究有害的评估。数据收集和分析：用标准的Cochrane方法来概括随机临床试验的数据。主要结论：我们无法发现任何随机临床试验评估治疗上消化道出血伴有急性或慢性肝脏疾病患者的抗纤溶氨基酸。我们无法确定准随机，历史控制，或可以评估危害的观察性研究。结论：没有随机临床试验进行了鉴定评估急性或慢性肝脏疾病患者上消化道出血的抗纤氨基酸的好处和危害。抗纤溶氨基酸益处和危害需要在随机临床试验的进行测试。除非随机临床试验来以评估权衡利益和危害关系，我们不建议也不反驳抗纤溶氨基酸为上消化道出血伴有急性或慢性肝脏疾病的患者的作用。
Abstract BACKGROUND:Upper gastrointestinal bleeding is one of the most frequent causes of morbidity and mortality in the course of liver cirrhosis. Patients with liver disease frequently have haemostatic abnormalities like hyperfibrinolysis. Therefore, antifibrinolytic amino acids have been proposed to be used as supplementary interventions alongside any of the primary treatments for upper gastrointestinal bleeding in patients with liver diseases. OBJECTIVES: To assess the beneficial and harmful effects of antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease. SEARCH METHODS: We searched the Cochrane Hepato-Biliary Group Controlled Trials Register (11 June 2012), Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2012, Issue 5 of 12), MEDLINE (Ovid SP) (1946 to June 2012), EMBASE (Ovid SP) (1974 to June 2012), Science Citation Index EXPANDED (1900 to June 2012), LILACS (1982 to June 2012), Clinical Trials Search Portal of the WHO (accessed June 18, 2012), and the Metaregister of Controlled Trials (accessed June 18, 2012). We scrutinised the reference lists of the retrieved publications. SELECTION CRITERIA: Randomised clinical trials irrespective of blinding, language, or publication status for assessment of benefits and harms. Observational studies for assessment of harms.DATA COLLECTION AND ANALYSIS: Data from randomised clinical trials were to be summarised by standard Cochrane Collaboration methodologies. MAIN RESULTS: We could not find any randomised clinical trials assessing antifibrinolytic amino acids for treating upper gastrointestinal bleeding in patients with acute or chronic liver disease. We could not identify quasi-randomised, historically controlled, or observational studies in which we could assess harms. CONCLUSIONS: No randomised clinical trials assessing the benefits and harms of antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease were identified. The benefits and harms of antifibrinolytic amino acids need to be tested in randomised clinical trials. Unless randomised clinical trials are conducted to assess the trade off between benefits and harms, we cannot recommend nor refute antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver diseases.